AARD
HealthcareAardvark Therapeutics, Inc.
$13.28
+$0.09 (+0.68%)
Jan 5, 2026
Price History (1Y)
Analysis
Aardvark Therapeutics, Inc. is a biotechnology company in the healthcare sector, with a market capitalization of $289.15 million and 33 employees. The company's industry classification remains unspecified. The financial health of Aardvark Therapeutics, Inc. indicates negative profitability, with gross margin, operating margin, and profit margin all at 0.0%. Returns on equity and assets are also negative, standing at -48.1% and -30.8%, respectively. The company's balance sheet shows a debt-to-equity ratio of 0.45 and a current ratio of 12.04. Cash reserves total $126.35 million, while debt amounts to $545,000. The valuation context for Aardvark Therapeutics, Inc. features a forward P/E ratio of -3.66 and an EV/EBITDA ratio of -3.02. The company does not pay dividends or issue payouts.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen, which is in the Phase 3 clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in the Phase 2 clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from the treatment of craniopharyngioma, including surgery or radiation. The company is also developing ARD-201, which is in the Phase 1 clinical trial for the treatment of obesity. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $289.15M
- P/E Ratio
- N/A
- 52-Week High
- $19.58
- 52-Week Low
- $4.88
- Avg Volume
- 197.77K
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 33